The shifting locus of risk-reduction: The critical role of HIV infected individuals

Social Work in Health Care

Volumn 42, Issue 3-4, 2006, Pages 112-132

  Indyk, Debbie ^a   Golub, Sarit A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Acquisition; Continuum; Prevention; Primary and secondary risk reduction; Transmission

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; ZIDOVUDINE;

CLINICAL TRIAL; DIZZINESS; HEARING LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY INJURY; NAUSEA; REVIEW; RISK ASSESSMENT; RISK REDUCTION;

EID: 33746742310     PISSN: 00981389     EISSN: 1541034X     Source Type: Journal    
DOI: 10.1300/J010v42n03_08     Document Type: Review

References (29)

1. Baeten, J.M., & Overbaugh, J. (2003). Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Current HIV Research, 1(1), 69-86.
2. Bowman, M.A,. & Spangler J.G. (1995). Screening, health promotion, and prevention in women. Primary Care, 22(4), 661-77.
3. Cardo, D.M., Culver, D.H., Ciesielski, C.A. et al. (1997). A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New England Journal of Medicine, 337, 1485-90.
4. Carpenter, C.C., Fischl, M.A., Hammer, S.M., Hirsch, M.S., Jacobsen, D.M., Katzenstein, D.A., Montaner, J.S., Richman, D.D., Saag, M.S., Schooley, R.T., Thompson, M.A., Vella, S., Yeni, P.G., Volberding, P.A. (1998). Antiretroviral Therapy for HIV Infection in 1996: Recommendations of an International Panel. Journal of the American Medical Association, 280(1), 78-86.
5. Cates, W. Jr., Chesney, M.A., & Cohen, M.S. (1997). Primary HIV infection - A public health opportunity. American Journal of Public Health, 87(12), 1928-1930.
6. Centers for Disease Control and Prevention. (1995). Case-control Study of HIV Seroconversion in Health-Care Workers after Percutaneous Exposure to HIV-infected Blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morbidity and Mortality Weekly Report, 44, 929-933.
7. Centers for Disease Control and Prevention (2003). Incorporating HIV prevention into the medical care of persons living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Morbidity and Mortality Weekly Report, 52(RR-12), 1-24.
8. Centers for Disease Control and Prevention (2005). Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR Morbidity and Mortality Weekly Report, 54(RR01), 1-20.
9. Conner, E.M., Sperling, R.S., Gelber, R., Kiselev, P., Scott, G., O'Sullivan, M.J., VanDyke, R., Bey, M., Shearer, W., Jacobson, R.L. et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. New England Journal of Medicine, 331, 1173-1180.
10. Dragoni, F., Mazzucconi, M.G., Cafolla, A. et al. (1996). Rapid liver failure related to chronic C hepatitis in a HIV seropositive hemophilic patient with severe immunodepression. Haematologica, 81(4):335-8.
11. Fellay, J., Boubaker, K., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., Hirschel, B., Vernazza, P., Francioli, P., Greub, G., Flepp, M., Telenti, A. & the Swiss HIV Cohort Study. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, 358(9290), 1322-1327.
12. Hammer, S.M. (1996). Advances in antiretroviral therapy and viral load monitoring. AIDS, 10(Suppl 3): S1-11.
13. Havlir, D.V. & Richman, D.D. (1996). Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Annals of Internal Medicine, 124(11), 984-994.
14. Kinloch-de Loes, S., Hirschel, B.J., Hoen, B. (1995).Acontrolled trial of zidovudine in primary human immunodeficiency virus infection. New England Journal of Medicine, 333, 408-413.
15. Lyons, F., Coughlan, S., Byrne, C. et al. (2002). Emergence of genotypic resistance in HIV-1-infected pregnant taking HAART to reduce mother-to-child transmission of HIV-1. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 24-28, (Abstract 892).
16. Mellors, J.W., Kingsley, L.A., Rinaldo, C.R. Jr., Todd, J.A., Hoo, B.S., Kokka, R.P., & Gupta, P. (1995). Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine, 122:573-9.
17. Mellors, J.W., Rinaldo, C.R. Jr., Gupta, P., White, R.M., Todd, J.A., Kingsley, L.A. (1996) Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 272, 1167-1170.
18. O'Brien, M.E., Clark, R.A., Besch, C.L., Myers, L., & Kissinger, P. (2003). Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. Journal of Acquired Immune Deficiency Syndrome, 34(4), 407-14.
19. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J., & Holmberg, S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. Journal of the American Medical Association, 338(13), 853-60.
20. Phillips, A.N. (1996). Reduction of HIV Concentration During Acute Infection: Independence from a Specific Immune Response. Science, 271, 497-499.
21. Powderly, W.G., Saag, M.S., Chapman, S., Yu, G., Quart, B., & Clendeninn, N.J. (1999). Predictors of optimal virological response to potent antiretroviral therapy. AIDS, 13(14), 1873-1880
22. Quinn, T.A. (1997). Acute primary HIV infection. Journal of the American Medical Association, 278, 58-62.
23. Rockstrojh, J.K., Spengler U., Sudhop, T. et al. (1996). "Immunosuppression May Lead to Progression of Hepatitis C Virus-associated Liver Disease in Hemophiliacs Coinfected with HIV. American Journal of Gastroenterology, 91(12): 2563-8.
24. Schacker, T.W., Hughes, J.P., Shea, T., Coombs, R.W., & Corey, L. (1998). Biological and virologic characteristics of primary HIV infection. Annals of Internal Medicine, 128(8), 613-620.
25. Shafer, A., Friedmann, W., Mielke, M., Schafer, A., Schwartlander, B., & Koch, M.A. (1991). The increased frequency of cervical dysplasia-neoplasia in women infected with the Human Immunodeficiency Virus is related to the degree of immunosuppression. American Journal of Obstetrics and Gynecology, 164:593.
26. Skolbekken J.A. (1995). The risk epidemic in medical journals. Social Science in Medicine, 40(3):291-305.
27. US Department of Health And Human Services (2005). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. April, 2005. Available at: http://aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf
28. Vittinghoff, E., Scheer, S., O'Malley, P., Colfax, G., Holmberg, S.D., & Buchbinder, S.P. (1999). Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. Journal of Infectious Diseases, 179(3), 717-720.
29. Wright, T.L., Hollander, H., Pu, X., Held, M.J., Lipson, P., Quan, S., Polito, A., Thaler, M.M., Bacchetti, P., & Scharschmidt, B.F. (1994). Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology, 20(5), 1152-1155.